















Name	KE)	Contestant	# Count	V

Senior Livestock Breeds Identification – 2020

INSTRUCTIONS: For each picture, use the columns on the right to choose the number or letter that indicates your answer for each livestock breed. Use capital letters and write neatly. **Seniors** provide answers for breed name, origin of breed, and important characteristics/traits. Each question is worth 5 points for each part of the question. (150 points total for Seniors).

	Breed Name	Origin of Breed	Important Traits
1.	30	D	G
2.	45	E	Н
3.	37	<u>I</u>	F
4.	27	J	D
5.	50	F	<u> </u>
6.	54	Н	J
7.	52	G	K
8.	1	C	C
9.	3	В	<u>A</u>
10	15	A	R

Breed Names – to be used	in answer column 1	by <u>Seniors</u>	
1. Angus 17. 2. Brahman 18. 3. Brangus 19. 4. Charolais 20. 5. Chianina 21. 6. Gelbvieh 22. 7. Hereford 23. 8. Limousin 24. 9. Maine Anjou 25. 10. Polled Hereford 26. 11. Red Angus 27. 12. Red Poll 28.	t Breeds Alpine American Cashmere Angora Boer Kiko Lamancha Nubian Oberhasli Pygmy Saanen Spanish Tennessee Fainting Toggenburg	Sheep Breeds 30. Cheviot 31. Columbia 32. Corriedale 33. Dorper 34. Dorset 35. Finnsheep 36. Hampshire 37. Katahdin 38. Merino 39. Montadale 40. Oxford 41. Polled Dorset 42. Rambouillet 43. Romney 44. Southdown 45. Suffolk 46. White Face Cross	Swine Breeds 47. Berkshire 48. Chester White 49. Duroc 50. Hampshire 51. Hereford 52. Landrace 53. Pietrain 54. Poland China 55. Spotted 56. Tamworth 57. Yorkshire

Origins of Breeds - to be used in answer column 2 by Intermediates Answers will be used ONLY once England A. Tees River Valley in England B. U.S. primarily at USDA Danish descendants Experiment Station in Jeanerette, LA. Developed in Butler and Warren Counties, OH, C. Aberdeen and Angus Counties US of Scotland Maine, U.S. D. Cheviot Hills of the border of Descendants of goats England and Scotland brough to America by E. Suffolk, England Spanish Explorers

Important Characteristics/Traits Origins of Breeds - to be used in answer column 3 by Seniors

$\underline{Beef\ Cattle\ Characteristics/Traits}$

- A. Disease resistance, heat resistance, hardiness, and maternal instinct.
- B. Moderate frame size, short broad head, wide-set eyes, and short horns.
- C. Excellent Meat Quality (nicely marbled), Calving Ease, and Hardy.

Goats Characteristics/Traits


- D. Meat yield, tough and hardy, agile and browsing ability.
- E. High Butterfat Content, Extended Breeding Season, Multi-Purpose use, (milk, meat and hide).


Sheep Characteristics/Traits


- Well-muscled carcass that is naturally lean, significantly tolerant of internal and external parasites.
- G. Easy lambing, mothering instinct, early maturity, vigorous forager and carcass conformation.
- H. Muscling and leanness, growth rate, and fertility.

Swine Characteristics/Traits


- I. Heavy Muscle, lean and good feed efficiency.
- J. Meat Quality (Intramuscular Fat).
- K. Prolificacy (litter size), milking ability, mothering ability.
















Inches







Senior Livestock and Meat Equipment Identification - 2020

INSTRUCTIONS: For each picture, use the columns on the right to choose the number or letter that indicates your answer for each piece of equipment. Use capital letters and write neatly. **Seniors** provide answers for livestock/meat equipment names and equipment use. Each question is worth 5 points (100 points total for Seniors).

	Equipment Name	Equipment Use
1.	34	0
2.	11	K
3.	12	P
4.	5	A
5.	36	G
6.	35	В
7.	33	K
8.	22	I
9.	39	M
10	0	N

Equipment Names – to be used i	n answer column 1 by <u>Seniors</u>	
Livestock	Equipment	Meat Equipment
Livestock 1. All Weather Paintstik. 2. Artificial insemination pipettes (Swine) 3. Bowl waterer 4. Balling gun 5. Barnes dehorner 6. Cattle clippers 7. Clipper comb 8. Clipper cutter 9. Currycomb 10. Disposable syringes 11. Drench gun 12. Ear notchers 13. Ear tag 14. Elastrator 15. Electric branding iron 16. Electric docker 17. Electric fence wire roller 18. Electric sheep shears 19. Emasculatome (Burdizzo) 20. Ewe prolapse retainer 21. Fencing pliers 22. Foot rot shears 23. Freeze branding iron 24. Hanging Scale	Equipment 26. Lamb tube feeder 27. Needle teeth nippers 28. Nipple waterer 29. Nose ring 30. Nose ring pliers 31. Obstetrical (O.B.) chain 32. Plastic Sleeve 33. Pistol Grip Syringe 34. Ralgro pellet injector 35. Ram marking harness 36. Rope Halter – Sheep 37. Rope Halter - Cattle 38. Rumen magnate 39. Scalpel 40. Scotch Comb 41. Semen Storage Tank 42. Slap tattoo 43. SYNOVEX Implant cartridge 44. SYNOVEX Implant gun 45. T-Post Electric Fence Insulator 46. Water Heater 47. Wood post electric fence insulator 48. Wool Card	Meat Equipment 49. Backfat ruler 50. Band saw 51. Bone dust scraper 52. Boning knife 53. Bowl chopper 54. Dehairing machine 55. Electrical stunner 56. Emulsifier 57. Ham net 58. Hand saw 59. Hard hat 60. Loin eye area grid 61. Meat grinder 62. Meat grinder auger 63. Meat grinder knife 64. Meat grinder plate 65. Meat grinder stuffing rod 66. Meat hook 67. Meat tenderizer 68. Meat trolley 69. Metal knife scabbard 70. Rubber apron 71. Sharpening steel 72. Smoke house 73. Thermometer
24. Hanging Scale25. Hand sheep shears		73. Thermometer74. Tumbler75. Vacuum sausage stuffer76. Wells saw

Equipment Uses – to be used in answer column 2 by Seniors

- A. Used to dehorn calves, sheep and goats.
- B. A device placed on rams that shows when a ewe has been serviced.
- C. Used to chop meat for sausages.
- D. Used to administer precise amounts of liquid medications to cattle, sheep, goats and horses. The hooked portion is placed in the animal's mouth to administer the liquid medication.
- E. An instrument used for the bloodless castration (young male calves, lambs, and goats) and docking of tails (young lambs and goats).
- F. Used to card (comb or rake) the wool on sheep prior to shearing.
- G. Used to lead (walk) sheep.
- H. Device used to deposit boar semen into reproductive tract of a gilt or
- Used to trim hooves of cattle, sheep, and goats to help prevent foot disease.

- J. An automatic waterer used to provide clean, fresh water to pigs.
- K. Used to give vaccinations to multiple animals without needing to reload the syringe with more vaccine.
- L. An instrument used for the bloodless castration of young male calves, lambs, and goats by severing (crushing) the testicular cord.
- M. Used by veterinarians for various surgical procedures, and by farmers for various health related and management practices (such as castration).
- N. Used to removed dirt and loose hair from cattle when grooming.
- O. Used to insert a RALGRO pellet (for growth promotion) under loose skin and above the cartilage on the back side of a beef calf's
- P. Used to clip small notches in a pig's ear to provide a form of permanent individual pig identification.

Name	KEY	Contestant #	County	

Senior Livestock Feed Identification – 2020

INSTRUCTIONS: For each sample, use the columns on the right to choose the number or letter that indicates your answer for each livestock feedstuff. Use capital letters and write neatly. **Seniors** provide answers for feedstuff name, nutrient group, and characteristics/uses of the feedstuff. Each question is worth 5 points (150 points total for Seniors).

	Feedstuff Name	Nutrient Group	Charact- eristics/ Uses
1.	70	V	M
2.	28	<u>C</u>	В
3.	13	P	N
4.	20	C	Н
5.	68	P	G
6.	27	M	D
7.	51	P	C
8.	57	C	A
9.	19	C	<u> </u>
10.	69	F	F

Feed Names – to be used in	answer column 1 by <u>Seniors</u>	
1. Alfalfa cubes	25. Grain sorghum (whole)	51. Soybean meal
2. Alfalfa pasture	26. Ground ear corn	52. Soybeans (whole)
3. Barley (whole)	27. Ground limestone	53. Spray-dried animal
4. Blood meal	28. Ground shelled corn	plasma
5. Brewers dried grain	29. Kentucky Bluegrass pasture	54. Spray-dried whey
6. Canola meal	30. L-lysine HCl	55. Steam flaked corn
7. Copper sulfate	31. L-threonine	56. Steam rolled barley
8. Corn distillers dried grain	32. L-tryptophan	57. Steam rolled oats
9. Corn distillers dried grain	33. Linseed meal	58. Steamed bone meal
with soluble	34. Liquid molasses	Sunflower meal
10. Corn gluten feed	35. Meat and bone meal	60. Tall Fescue hay
11. Cottonseed (whole)	36. Millet (whole)	Tall Fescue pasture
12. Cottonseed hulls	37. Oats (whole)	62. Timothy hay
13. Cottonseed meal	38. Oat hulls	63. Timothy pasture
14. Cracked shelled corn	39. Orchardgrass hay	64. Trace-mineral premix
15. Crimped oats	40. Orchardgrass pasture	65. Trace-mineralized salt
16. Defluorinated rock	41. Oyster shells	66. Triticale (whole)
phosphate	42. Peanut meal	67. Tryptosine
17. Dicalcium phosphate	43. Red Clover hay	68. Urea
18. DL-methionine	Red Clover pasture	69. Vegetable oil
19. Dried Beet pulp	45. Roller dried whey	Vitamin premix
20. Dried molasses	46. Rye (whole)	71. Wheat (whole)
21. Dried skim milk	47. Salt, white	72. Wheat bran
22. Feather meal	48. Santoquin	73. Wheat middlings
23. Fish meal	49. Shelled corn	74. White Clover hay
	50. Soybean hulls	75. White Clover pasture

Feeds Nutrient Groups – to be used in answer column 2 by Seniors

(You may use the letter more than once!!)

- B. By-product feed
- C. Carbohydrate (energy)F. Fats (energy)
- v)
- M. Mineral P. Protein
- V. Vitamin

Important Characteristics/Uses of Feedstuffs – to be used in answer column 3 by and Seniors

- A. These have been passed through a roller to produce a flake. Primarily used in horse feeds or young animals.
- B. Shelled corn that has been mechanically processed through a hammer mill.
- C. Most widely used protein supplement in the U.S. Excellent source of protein and amino acids. Produced by grinding the flakes that remain after oil is extracted from this.
- D. A natural source of calcium that is relatively inexpensive used in livestock, horse and poultry diets. Also called calcium carbonate.
- E. Bulk density = 32 pounds/bushel
- F. A very potent energy source supplying about 2.25 times more energy than starch or sugar.
- G. A source of nitrogen. Should be fed to ruminants only. Need to be mixed with a feed source that contains energy.

- H. Dried by-product of the manufacture of sugar from either sugar beets, or more commonly, sugarcane.
- Produced by extracting the sugar from sugar beets and drying the remaining pulp.
- J. High in protein, and contains active immunoglobulins.
- K. Good source of ruminant bypass protein and used in limited amounts in pig diets.
- L. Also referred to as bluestone.
- M. May contain both fat soluble and water soluble vitamins. Various feedstuffs (such as rice hulls, soybean meal, corn gluten meal and wheat middlings) are used as carriers in this.
- N. Produced by grinding the flakes that remain after oil is extracted from whole cottonseeds.

Senior Hay Judging Class – 2020

. -	• • • • • •	• 4	
Name	Contestant #	County	

(50 points possible)

Placing Score	
_	
University of Kentucky College of Agriculture	
Animal Sciences Department	A 1234
	B 1243
Contestant's Name	C 1324
contestant s rame	D 1342
	E 1423
	F 1432
	G 2134
A 11	H 2143
Address	I 2314
	J 2341
	K 2413
	L 2431
	M 3124
County	N 3142
	O 3214
	P 3241
	Q 3412
Class	R 3421
Hay Judging Class	S 4123
	T 4132
	U 4213
	V 4231
	W 4312
	X 4321

[Turn over for Scenario and Forage Analysis Information]

Scenario:

You have kept a group of replacement heifers to winter and breed this spring. As of February 22nd the average weight of the heifers is 675 pounds. The heifer calves are up to date on vaccinations. Target weight for heifers at breeding is 800 pounds with a projected breeding date of May 22nd. Rank the four hay samples in the order that you would utilize them as the most effective source of forage for these replacements. A 12% pelleted beef feed is being fed, but mainly as a means to break heifers to come and calm cattle down. Ultimately the hay you choose will be the main source of feed until spring grass arrives.

Nutrient Requirements for 675 pound heifer to gain 1.3 pounds per day.

Dry Matter: 16.2 (lbs.) Crude Protein: 10.1%

TDN: 64%

Forage Analysis

	Hay Lot #1 2019 2 nd Cutting Grass Mixture	Hay Lot #2 2018 2 nd Cutting Grass Mixture	Hay Lot #3 2017 Late Cut Grass Mixture	Hay Lot # 4 2018 1st Cutting Grass Mixture
Dry matter	88.9%	88.6%	88.9%	88.6%
Crude protein	12.7%	10.7%	8.5%	10.6%
Acid detergent fiber (ADF)	44.9%	44.6%	49.7%	44.8%
Neutral detergent fiber (NDF)	66.2%	67.5%	69.4%	67.3%
Total digestible nutrients (TDN)	66.0%	64.5%	52.0%	63.6%
Price per ton	\$104	\$105	\$85	\$110

Senior Hay Judging Class – 2020

Official: 1-2-4-3 Cuts: 3-2-5

(50 points possible)

Placing Score			
lacing Beore			
niversity of Kentucky			
ollege of Agriculture nimal Sciences Department	A	1234	45
mmai Sciences Department	B	1 2 4 3	50
	C	1324	38
ontestant's Name	D	1 3 4 2	36
	E	1423	48
	F	1432	41
	G	2134	42
	Н	2 1 4 3	47
ddress	I	2 3 1 4	32
	J	2 3 4 1	27
	K	2413	42
	L	2 4 3 1	32
	M	3 1 2 4	28
ounty	N	3 1 4 2	26
	O	3 2 1 4	25
	P	3 2 4 1	20
	Q	3 4 1 2	21
lass	R	3 4 2 1	18
Hay Judging Class	S	4 1 2 3	43
	T	4132	36
	U	4213	40
	V	4231	30
	W	4 3 1 2	26
	X	4 3 2 1	23

[Turn over for Scenario and Forage Analysis Information]



FACT SHEET


Global Experience

IMPROVEST (gonadotropin releasing factor analog – diphtheria toxoid conjugate) is an FDA-approved veterinary prescription product that is a safe and effective alternative to physical castration¹ to manage unpleasant aromas that can occur when cooking pork from some male pigs. It's a protein compound that works like an immunization to temporarily protect against off odors in pork. Male pigs are given IMPROVEST later in the finishing phase to manage off odors, eliminating the need for physical castration.

This technology has been approved in more than 60 countries, including the European Union and Japan, under the related global brands IMPROVAC®, INNOSURE® and VIVAX. This fact sheet summarizes how this new technology has been adopted in a variety of pork-producing markets around the world.

Australia (1998, IMPROVAC)

Historically, Australia has been primarily a non-castrate market. As such, fresh pork buyers have to be particularly careful to avoid meat with off odors, so they actually pay a premium for meat from female pigs. Initially IMPROVAC was used mainly with males pigs destined for export markets that demanded high-value branded pork. Recently, the market for IMPROVAC in Australia has begun to greatly accelerate in the high value, fresh branded pork market as major industry stakeholders are expanding branding efforts to improve the reputation of pork. Pork from pigs that receive IMPROVAC is characterized as "assured of high eating quality."



Countries where IMPROVEST, or related global brands, have been approved.

Now approved in more than 60 countries this immunological technology continues to gain acceptance around the world. This technology is approved in these countries:

Australia Latvia Austria Liechtenstein Argentina Lithuania Belgium Luxembourg Bulgaria Malaysia Malta Brazil Canada Mexico Chile New Zealand China Netherlands Colombia Nicaraqua Costa Rica Norway Croatia Panama Cyprus Peru Czech Republic **Philippines** Denmark Poland Dominican Portugal Romania Republic Ecuador Russia El Salvador Serbia Slovakia Estonia Finland Slovenia France South Africa Germany Spain Sweden Greece Guatemala Switzerland Honduras Thailand Hungary UK Iceland Ukraine Ireland United States Uruguay Italy Japan Venezuela Korea Vietnam

Improvest°

(Gonadotropin Releasing Factor Analog-Diphtheria Toxoid Conjugate, 0.2mg/mL)

Brazil (2007, VIVAX)

More than half of the overall male pigs being marketed, including those in both small and large operations, are using VIVAX to manage off odors in pork. Brazil is a pork market with a highly consolidated production system. It has both significant domestic and export pork markets. Sales of VIVAX are made directly to key farmers, with Zoetis providing full-service administration. Uptake of the technology in Brazil has been rapid and continues to grow.

Argentina (2008, IMPROVAC)

After the approval of IMPROVAC in 2008, the administration created a new category of pork called "Entire male immunologically castrated." There are three main integrators in Argentina. Two of these companies are using IMPROVAC, along with some small producers.

Chile (2008, IMPROVAC)

Two companies in Chile are currently exporting pork to Japan.

Columbia and Venezuela (2008, IMPROVAC)

Columbia has the highest market penetration in the world. IMPROVAC is being used by non-integrated small pig-producing companies.

South Africa (2008, IMPROVAC)

This is an entire male market. Meat quality and behavior are key drivers for selling the product in South Africa.

Thailand (2008, IMPROVAC)

The largest food production company in Thailand is adopting the product. Some pork from pigs given IMPROVAC sells for a premium price.

European Union (2009, IMPROVAC) and Switzerland (2008, IMPROVAC)

For some time, animal welfare advocacy groups have petitioned member states, the food chain and even the E.U. to place limits on or ban physical castration. As a result, on Dec. 15, 2010, a voluntary committee of major pork chain stakeholders committed to the "European Declaration on the Alternatives to Surgical Castration of Pigs" (Brussels Declaration), which outlines clear measurable actions over the next seven years. The declaration ensures that after Jan. 1, 2012, no physical castration will take place without recognized analgesia and/or anesthesia, and after Jan. 1, 2018, no physical castration will take place at all. Signatories of this declaration included groups and companies such as the Liaison Center for the Meat Processing Industry in the European Union, Federation of Veterinarians of Europe, European farmers and European agri-cooperatives, Danish Agriculture and Food Council, German Meat Association, German Retail Association, and many others.

Anticipating the shifting market environment, European retailers, such as Colruyt and Okay, announced plans in August 2010 to stop selling pork from physically castrated pigs by the end of the year, and adopt IMPROVAC as the best option for off-odor control in 100 percent of their pork supply. The farmers who supply these retailers agreed to stop physical castration and have now incorporated IMPROVAC in their standard practice for rearing male pigs. The Colruyt Group based its decision on the results of independent tests of various off-odor control alternatives. The

Globally, more farmers are adopting this innovative immunological solution as an alterative to physical castration to manage off odors in pork. results confirmed that immunization was as effective as physical castration in reducing off odors and provided a higher quality eating experience. Since Jan. 1, 2011, the only pork from male pigs available at its retail stores is from pigs raised using IMPROVAC.

Poland and Romania (2009, IMPROVAC)

Large integrators are especially interested in adopting this technology because of its feed efficiency and economic benefits.

Japan (2010, IMPROVAC)

Japan has had no restrictions on receiving pork imported from countries using this technology, and now with its 2010 regulatory approval, its use in-country is growing. There are no issues anticipated in exporting U.S. pork from pigs raised using IMPROVEST to this country.

China (2010, IMPROVAC)

The approval of IMPROVAC in China has been welcomed by government officials, who see the technology as more efficient and environmentally-friendly way to rear male pigs. Initial adoption is growing.

Important safety information

The prescribing veterinarian is responsible for informing those who administer the product of its proper use and associated risks. In the event of accidental self injection, reproductive physiology of both men and women, as well as pregnancy, may be adversely affected. It is important to remember that these risks are not associated with eating pork from pigs that have been given IMPROVEST.

FDA Freedom of Information Summary. IMPROVEST (gonadotropin releasing factor analog-diphtheria toxoid conjugate) Sterile Solution. NADA 141-322

^{2.} These odors occur naturally in mature male pigs. They do not represent a food safety concern, but need to be controlled to ensure a high-quality eating experience.

Improvest®

(Gonadotropin Releasing Factor Analog-Diphtheria Toxoid Conjugate, 0.2 mg/mL)

Sterile Solution for Injection

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: IMPROVEST is a sterile solution containing Gonadotropin Releasing Factor Analog-Diphtheria Toxoid Conjugate. Each mL contains 0.2 mg Gonadotropin Releasing Factor Analog-Diphtheria Toxoid Conjugate, 150 mg of diethylaminoethyl-dextran hydrochloride, 1 mg chlorocresol, sodium hydroxide as needed to adjust pH and water for injection.

INDICATIONS FOR USE: IMPROVEST is indicated for the temporary immunological castration (suppression of testicular function) and reduction of boar taint in intact male pigs intended for slaughter.

DOSAGE AND ADMINISTRATION: IMPROVEST should be administered via subcutaneous injection into the post auricular region of the neck. A safety injector should be used, preferably one which has a dual safety system providing both a needle guard and a mechanism to prevent accidental operation of the trigger. Each intact male pig should receive two 2-mL doses of IMPROVEST. The first dose should be administered no earlier than 9 weeks of age. The second dose should be administered at least 4 weeks after the first dose. Pigs should be slaughtered no earlier than 3 weeks and no later than 10 weeks after the second dose. In case of misdosing, the animal should be re-dosed immediately.

CONTRAINDICATIONS: Do not use IMPROVEST in intact male pigs intended for breeding because of the disruption of reproductive function. Not approved for use in female pigs and barrows.

WARNINGS



WITHDRAWAL PERIODS:

No withdrawal period is required when used according to labeling.



Not for Human Use. Keep Out of Reach of Children.

USER SAFETY WARNINGS:

Warning for person administering IMPROVEST: Accidental self injection could affect reproductive physiology of both men and women and may adversely affect pregnancy. Pregnant women should not administer this product. Women of childbearing age should exercise extreme caution when handling this product. Special care should be taken to avoid accidental self injection and needle stick injury when administering the product. Protective clothing including, but not limited to, safety glasses and gloves should be worn. Use a safety injector, preferably one which has a dual safety system providing both a needle guard and a mechanism to prevent accidental operation of the trigger. In case of eye contact, rinse immediately with copious amounts of water. In case of skin contact, wash immediately with soap and water. The product should be stored safely out of the reach of children. As a reminder, it is the prescribing veterinarian's responsibility to inform drug administrators of the user safety warnings associated with IMPROVEST.

Advice to the user in the event of accidental self injection: In the event of accidental self injection, wash the injury thoroughly with clean running water. Seek prompt medical attention and take the package leaflet with you. Do not administer the product, and/or any other product with a similar action, in the future.

Advice to the physician: Accidental self injection could affect reproductive physiology of both men and women and may adversely affect pregnancy. If self injection with IMPROVEST is suspected, reproductive physiology should be monitored by assay of testosterone or estrogen levels (as appropriate). The risk of a physiological effect is greater after a second or subsequent accidental injection than after a first injection. The patient should be advised not to administer IMPROVEST, and/or any other product with a similar action, in the future.

For customer service, to report suspected adverse reactions or to obtain a copy of the Material Safety Data Sheet (MSDS) call 1-888-963-8471.

PRECAUTIONS: Subcutaneous injection in intact male pigs can cause a transient local injection site reaction that may result in trim loss at slaughter.

ADVERSE REACTIONS: The field study observations from field effectiveness studies were consistent with the observations made during the target animal safety studies of transient inflammation at the injection sites. IMPROVEST did not cause unusual clinical signs or an unexpected frequency or severity of injection site reactions. Adverse events, as reported, were not uniquely attributable to IMPROVEST.

TARGET ANIMAL SAFETY:

Margin of Safety: The safety of two doses of IMPROVEST was evaluated in intact male swine. Thirty 9-week old intact boars received two subcutaneous doses of IMPROVEST in the same location 14 days apart. The boars received one of three treatments: Saline Control (12-mL), IMPROVEST at the intended dose (2-mL, 1X), or IMPROVEST at 6 times the intended dose (12-mL, 6X). Boars were clinically monitored daily. In addition, observation and measurement of injection sites, body weight, quantitative feed consumption, hematology, and clinical chemistry analyses were also obtained. A complete postmortem examination was conducted on each boar

14 days after the second injection. IMPROVEST, administered subcutaneously at the label dose (2-mL) resulted in mild transient injection site reactions at the 1X dose and caused clinical signs of systemic inflammation at 6X the intended dose. The signs of inflammation included depression, stiffness of the neck lasting up to five days, reduction in feed intake, and lower body weights. Multiple swollen joints and associated lameness, which may be signs of systemic inflammation, were observed in one 6X boar. Evaluation of blood work revealed increased white blood cell counts (eosinophilia and neutrophilia); slight increases in total serum protein (above normal reference range in 50% of the 6X boars) and globulin (above the normal reference range in 40% of the 6X boars); and slight decreases in serum albumin in 6X boars. Injection sites for the 6X boars showed clinically detectable firmness persisting in all animals for 14 days after the second injection. Pain and sensitivity at the injection site persisted for up to five days, and erythema and heat were more prominent in the 6X boars than in the 1X boars. Mild to moderate chronic inflammation and discoloration in the subcutaneous tissues at the injection site were observed. In all IMPROVEST treated boars, atrophy of testes, prostate, and bulbourethral glands were observed as expected consequences associated with the intended effect of the drug. At the label 2-mL dose, IMPROVEST may cause transient injection site inflammation.

Injection Site Safety: Injection site safety was evaluated following the injection of IMPROVEST into healthy 17-week old boars. The treated boars received two 2-mL doses of IMPROVEST into the same injection site location 28 days apart, while the control boars received saline. Daily monitoring included clinical evaluation and observation and measurement of injection sites. Two days after the second injection, postmortem observations of injection sites were conducted. All clinical signs of observable injection site swelling were resolved within 24 hours, and pain on palpation resolved by 48 hours post-injection. Firmness persisted for up to 11 days after the first injection in 10% of boars. Gross injection site alterations consisted of subcutaneous edema with tan or red discoloration. Two 2-mL injections of IMPROVEST, administered 28 days apart into the same location resulted in transient injection site reactions following each injection and resulted in discoloration of tissue at the injection site which was observable approximately 48 hours after the second injection.

Field Safety: During the conduct of the nine location field effectiveness study, IMPROVEST did not cause unusual clinical signs or an unexpected frequency or severity of injection site reactions. The field safety observations from this study were consistent with the observations made during the target animal safety studies of transient inflammation at the injection sites. Adverse events, as reported, were not uniquely attributable to IMPROVEST.

EFFECTIVENESS: IMPROVEST is an injectable sterile solution containing an incomplete analog of natural gonadotropin releasing factor (GnRF) conjugated to diphtheria toxoid in an adjuvanted formulation. Immunization with a two dose regimen of IMPROVEST, with a four week interval between doses, stimulates the pig's immune system to produce antibodies which can neutralize its own GnRF. Pigs given an initial dose of IMPROVEST are immunologically primed but do not produce sufficient antibodies to have any physiological effect. Following receipt of the second dose, the pig's immune system responds with a strong antibody response. These antibodies bind to and neutralize circulating GnRF in the bloodstream. Neutralization of GnRF blocks the hypothalamic-pituitary-gonadal endocrine axis, thereby suppressing testicular function, including both sex hormone production and reproductive capability, thereby providing temporary immunological castration in these injected boars.

Evidence of temporary immunological castration was provided in a series of studies showing that within 1-2 weeks after the second injection of IMPROVEST, anti-GnRF antibody levels increase significantly. With this rise in anti-GnRF antibodies, the levels of gonadal sex hormones were substantially reduced, the size of the testes, and spermatogenesis suppressed, as was the expression of typical male behaviors (aggression and sexual, e.g., mounting). Full immunological castration was demonstrated to last from 3 to 10 weeks after the second dose.

IMPROVEST injected boars will start to return to full reproductive function at a variable period after this time, as evidenced by increases in male sex hormones, testicle size, and intact male behavior. IMPROVEST should not be used in boars intended for breeding purposes.

Evidence to assess the acceptability of pork from IMPROVEST treated pigs was provided through a series of consumer taste panels using consumers deemed sensitive to the taste of "tainted" meat. The presence of boar taint was evaluated on the basis of pork aroma and flavor and not by chemical analysis. Four consumer taste panel studies were conducted to demonstrate the difference of pork generated from IMPROVEST treated boars and intact boars. A surgically castrated male group was not evaluated during these studies. In these four studies, 767 sensitive consumers evaluated cooked pork loin samples from IMPROVEST treated and intact boars. These pigs were raised to market weight, injected with IMPROVEST as per product labelling and slaughtered 3 to 10 weeks after receipt of the second IMPROVEST injection. The consumers found the aroma and flavor of pork from the IMPROVEST injected pigs to be more acceptable than from the intact boars in all four studies.

STORAGE INFORMATION: Store under refrigeration at 2°-8°C (36°-46°F). Once broached, product may be stored under refrigeration for 28 days. Store bottles in carton until used. Protect from light. Protect from freezing.

HOW SUPPLIED: IMPROVEST is available in the following package sizes: 20 mL bottle, 100 mL bottle, 250 mL bottle, 500 mL bottle.

Revised: January 2013

NADA # 141-322, Approved by FDA



Name	Contestant#	County	
------	-------------	--------	--


Senior Individual Quality Assurance – 2020


You recently started working at a farrow to finish swine operation. Each year the operation keeps back 30 prospect boars. Over time of developing those boars the operation then starts to cull down to 15 boars. Instead of taking a discount on intact males, the operation has decided to feed them out while immunologically castrating them using Improvest. The operation will then privately market the product to consumers after the boars are finished out. Use the **Improvest label** and your knowledge of quality assurance management to answer the **10 questions** below relating to quality assurance. **Circle your answers**. (10 questions worth 5 points per question for 50 total points).

1.	mprovest should be used on which of the following?					
	A.) Intact boars during o	ffseason of bre	eeding	C.) Intact boars go	ing to slaughter	
	B.) Barrows for increase	d weight gain		D.) Both A & c		
2.	How should Improvest be administered?					
	A.) On the skin		C.)	In the nose		
	B.) Intramuscular		D.)	Subcutaneously		
3.	When an adverse reaction occurs from using Improvest what should you do?					
	A.) Give another shot of	of Improvest	(C.)	No known treatment		
	B.) Give 3 CC of Penicil	lin	D.)	Drench with water		
4.	If you have a group of pigs at 8 weeks of age, what dosage would you use?			e?		
	A.) 1½ mL	C.) 2 mL				
	B.) ¼ mL	D.) Not i	ntended [.]	for hogs younger than	9 weeks of age	


5. What is the best way to fully understand how	w to properly use Improvest?				
A.) Follow your veterinarians instructions and/or the label insert for Improvest					
B.) Carefully read and follow the entire insert for Improvest but do not consult your veterinarianC.) Take the advice of your neighbor who has been using the product for 3 years					
. What package size is Improvest not supplied	in?				
A.) 20 ML B.) 75 ML C.) 250 M	IL D.) 500 ML				
If accidental user self-injection happens what should you do?					
A.) Wash with clean running water	A.) Wash with clean running water				
B.) Seek prompt medical attention					
C.) Do not administer product with similar action in future					
D.) All of the above					
. When injecting Improvest we should not give	e it?				
A.) In the Loin B.) In the vein C.) Under s	kin on Neck (D.) Both A and B				
. Improvest can be obtained by which of the fo	ollowing ways?				
A.) Through a licensed veterinarian	C.) Ordering Online				
B.) Kentucky Department of Agriculture	e D.) None of the above				
0. Improvest should be stored at	?				
A.) 2 degrees C to 8 degrees C	C.) 36 degrees F to 46 degrees F				
B.) Room temperature	D.) Both A and C				












5.










9.



10.



Name	KEY	Contestant #	County	
11ac_			Oodiity	

Senior Retail Meat Cut Identification - 2020

INSTRUCTIONS: For each picture, use the columns on the right to choose the number or letter that indicates your answer for each retail meat cut. Use capital letters and write neatly. **Seniors** provide answers for retail cut name, species of cut, and wholesale cut of origin. Each question is worth 5 points (150 points total for Seniors).

	Retail Cut Name	Species of Cut	Wholesale Cut of Origin
1.	35	В	G
2.	57	L	L
3.	61	L	M
4.	70	P	P
5.	11	В	В
6.	21	В	D
7.	54	L	K
8.	67	P	R
9.	48	В	<u> </u>
10.	72	P	L

Beef Retail Meat Cuts 1. Beef for stew	17 6:-1-:111	22 D-44
	17. Sirloin steak, shell	32. Bottom round roast
2. Brisket, point half	18. Sirloin steak, boneless19. Tenderloin steak	33. Bottom round steak
3. Brisket, whole		34. Eye round roast
4. Arm roast	20. Porterhouse steak	35. Eye round steak
5. Arm roast, boneless	21. T-bone steak	36. Heel of round roast
6. Arm steak	22. Top loin steak	37. Rump roast, boneless
7. Arm steak, boneless	23. Top loin steak, boneless	38. Round steak
8. Blade roast	24. Short ribs	39. Round steak, boneless
9. Blade steak	25. Skirt steak	40. Tip roast
10. 7-bone roast	26. Rib roast, large end	41. Tip roast, cap off
11. 7-bone steak	27. Rib roast, small end	42. Tip steak
12. Flank steak	28. Rib steak, small end	43. Tip steak, cap off
13. Sirloin steak, flat bone	29. Rib steak, small end, boneless	44. Top round roast
14. Sirloin steak, pin bone	30. Ribeye roast	45. Top round steak
15. Sirloin steak, round bone	31. Ribeye steak	46. Cross cuts
Sirloin steak, wedge bone		47. Cross cuts, boneless
		48. Kidney
Lamb Retail Meat Cuts		
49. Breast	Sirloin chop	Rib roast
Breast riblets	Leg sirloin half	62. Rib roast, boneless
American style roast	57. Loin chop	63. Shanks
52. Leg Center slice	58. Loin double chop	64. Blade chop
53. French style roast	59. Loin roast	65. Neck slice
54. Leg shank half	60. Rib chop	66. Shoulder square cut
Pork Retail Meat Cuts		
67. Fresh ham center slice	74. Center rib roast	81. Arm roast
68. Fresh ham rump portion	75. Center loin roast	82. Arm steak
69. Fresh ham shank portion	76. Loin chop	83. Blade Boston roast
70. Fresh side pork	77. Rib chop	84. Sliced bacon
71. Blade chop	78. Sirloin chop	85. Smoked jowl
72. Blade roast	79. Top loin chop	86. Smoked Canadian
73. Butterfly chop	80. Arm picnic roast	Style Bacon
,	r	

Species of Cut – to be used in answer column 2 by Seniors (You may use the letter more than once!!) B. Beef L. Lamb P. Pork

Wholesale Cut of Origin – to be used in answer column 3 by Seniors Beef Wholesale Cuts Lamb Wholesale Cuts Pork Wholesale Cuts J. Breast P. Belly (Side, Bacon) A. Brisket B. Chuck K. Leg Q. Boston Butt C. Flank L. Loin R. Ham D. Loin M. Rack S. Jowl E. Plate N. Shank T. Loin O. Shoulder U. Picnic Shoulder F. Rib G. Round H. Shank I. Variety cut

Senior Retail Meat Judging Class 1 – 2020

Name	KEY	Contestant #	County

Placing is worth a possible 50 points

Placing: 2,1,3,4 Cuts:2-2-4

Contestant Number			
Placing Score			
University of Kentucky College of Agriculture			
Animal Sciences Department	A	1234	48
	В	1243	44
Contestant's Name	С	1324	44
Contestant's Name	D	1342	36
	Е	1423	36
	F	1432	32
	G	2134	50
	Н	2143	46
Address	I	2314	48
Audress	J	2341	42
	K	2413	40
	L	2431	38
·	M	3124	42
	N	3 1 4 2	34
County	0	3 2 1 4	44
county	P	3 2 4 1	38
	Q	3 4 1 2	28
	R	3 4 2 1	30
	S	4123	30
Class: 1: Beef Loin	Т	4132	26
	U	4213	32
	V	4231	30
	W	4312	24
	X	4 3 2 1	26

Senior Retail Meat Judging Class 2 – 2020

Name	Kev	Contactant #	Country
name	nev	Contestant #	County

(Placing is worth a possible 50 points and each of the 5 questions is worth 10 points for 50 possible points – Grand Total of 100 possible points)

	Placing: Cuts: 2-		Contestant Number
			Placing Score
			University of Kentucky College of Agriculture
26	1234	A	Animal Sciences Department
24	1243	В	
34	1 3 2 4	С	Contestant's Name
40	1 3 4 2	D	Contestant's Name
30	1 4 2 3	Е	
38	1 4 3 2	F	
24	2 1 3 4	G	
22	2 1 4 3	Н	
30	2 3 1 4	I	
34	2 3 4 1	J	Address
26	2413	K	
32	2 4 3 1	L	
40	3 1 2 4	M	
46	3 1 4 2	N	
38	3 2 1 4	0	_
42	3 2 4 1	P	County
50	3 4 1 2	Q	
48	3 4 2 1	R	
34	4123	S	
42	4132	T	Class 2: Ribeyes
32	4213	U	Class 2. Hibeyes
38	4231	V	
		W	
46		X	
48	4312	WX	

[Turn over and answer questions on the back of this sheet]

QUESTIONS

1)	Which Ribeye has the most Ribeye area?3
2)	Between 1 and 4 which Ribeye has more marbling?1
3)	Between 2 and 3 who has less seam fat?3
4)	Which Ribeye has the most cherry red color?2_
5)	T/F are all of the Ribeye's USDA Choice?T

Senior Quiz - 2020

Carefully circle the correct answer to each of the questions below. (Each question is worth 2 points each

	•	al of 50 points)	n or the q	juestions be	iow. (Lacir question is worth 2 points
1.) '	Which	one of the following is not a	recognize	d USDA Ou	ality Grade for a lamb carcass?
,	a.	Select	•	. Prime	many cause for warming contents.
	b.			l. Choice	
	Which pigs?	one of the following would b	e a manag	gement techr	nique used in processing a litter of baby
	a.	Docking Tails			c. Clipping needle teeth
	b.	Giving an iron injection			d. All of the above
3.)	The pe	eriod of time from calving to f	ïrst heat is	s called	?
	a.	Generation interval		c. La	ctation
	b.	Postpartum interval		d. Ge	estation
4.)	A heif	er born twin to a bull is called	a what?		
	a.	Freemartin	c	. Heiferette	
	b.	Deformity	d	l. Sterile Hei	fer
5.)	The le	ngth of the gestation period fo	or swine is	·	_?
	a.	336 days	c	. 150 days	
	b.	107 days	d	l. 114 days	
6.) \	What o	does EPDs stand for in the live	estock ind	ustry?	
	a.	Expected Progeny Difference	es		c. Exceptional Pig Duroc
	b.	Every Progeny Differences			d. Ewes, Pigs and Dogs
7.)	The id	eal pork quality standard is		?	
	a.	DFD	c. PSE		
(b.	RFN	d. None	of the above	e
8.) '	What i	is the average gestation length	in goats?		
	a.	120 days	C	. 150 days	
	b.	80 days	d	l. 160 days	-

9.) Which	one of the following rams wo	ald pass on only Sc	crapie susceptible genes to their progeny?			
a.	QRNn	c. RRNN				
b.	QQNN	d. RRNn				
10.) Which	one of the following diseases	is related to a lack	of vitamin E and selenium in sheep?			
a.	White Muscle Disease		c. Shipping Fever			
b.	Curley Calf Syndrome		d. Leptospirosis			
11.) Whic	h of the following is considered	d a <i>Bos Taurus</i> bre	ed?			
a.	Angus	c. Red Poll				
b.	Brahman	d. Both A	and C			
12.) What	is most important when select	ing breeding anima	als to be used as replacements?			
a.	Color and breed	C.	Structural and reproductive soundness			
b.	Bone and foot size	d.	Muscle			
13.) Whic	h breed of swine would you se	lect for mothering	ability?			
a.	Yorkshire	c .]	Duroc			
b.	Hampshire	d.	Poland China			
,	ch of the following beef carcass remiums for both USDA Quali		e most dollars if sold on a "grid" that			
a.	USDA Select, Yield Grade 1.	8	c. USDA Prime, Yield Grade 4.9			
b.	USDA Prime, Yield Grade 2.	9	d. USDA Choice, Yield Grade 2.9			
15.) What	is the most popular breed of ca	attle (by registratio	n numbers) in the USA?			
a.	Hereford	c. Maine-A	anjou			
b.	Simmental	d. Angus				
16.) What	16.) What is the common dressing percent for hogs?					
a.	52 %	c. 72 %				
b.	88 %	d. 65 %				
17.) Whic	h of the following might cause	scours in a herd of	meat goats?			
a.	Change in feed ration		c. Coccidiosis			
b.	Parasites		d. All of the above			

18.) On av	verage how many pounds of grain doe	es it take to get one pound of gain on a market cattle?
a.	12.5 – 13.0	c. 5.5 – 6.5
b.	2.5 - 3.5	d. 8.5 – 9.5
19.) What	is dystocia?	
a.	A genetic defect	c. Light muscled
b.	Calving difficulty	d. None of the above
20.) Which	h of the following is not a vitamin?	
a.	Vitamin K	c. Ascorbic acid
b.	Thiamine	d. All of these are vitamins
21.) Which	h of these is a monogastric?	
a.	Cow	c. Barrow
b.	Ram	d. Steer
22.) What	is the gestation length in sheep?	
a.	100 days	c. 244 days
b.	150 days	d. 283 days
23.) The fo	emale reproductive organ where ferti	lization usually occurs is called?
a.	Ovary	c. Cervix
b.	Oviduct	d. Uterus
24.) What	is the average length of gestation in o	cattle?
a.	150 days	c. 365 days
b.	244 days (d. 283 days
25.) The N	North American International Liveston	ck Exposition is held where?
a.	Denver	c. Houston
b.	Lexington	d. Louisville

County	_KEY	
Team Members		

Senior Team Breeding Exercise - 2020

Your group is working with Farmer Fred to help him decide which Hampshire Rams to buy to breed to his flock. Farmer Fred needs 2 rams and has a budget of \$2,000. The rams bought will be utilized in a Central Kentucky flock, and will be mated to Dorset x blackface crossbred ewes. All progeny will be sold to slaughter. Depending on market conditions, lambs may be sold into ethnic market at 80-100 pounds live weight. Alternatively, the lamb crop is fed to 130-150 pounds and sold directly to a processor on a carcass weight basis. Please select 2 rams that would best fit this situation for Farmer Fred and answer the 10 questions below. Additionally you will need to discuss your choices with the contest official.

[The questions are worth 10 points each for a total of 100 possible points and your discussion with the Official is worth 100 possible points for a grand total of 200 possible points.]

Animal ID	Tag#	Birth Type	Codon 171	Weaning Weight (kg)	Post Weaning Weight (kg)	Maternal Milk (kg)	Maternal Lambs Weaned (kg)	Loin Muscle Depth (mm)	Price
1	8658	TW	QR	+3.3	+5.0	+0.3	0.0	+1.4	\$1150
2	8648	TW	RR	+0.3	+1.8	+0.1	+1.0	0.0	\$600
3	8679	TW	RR	+2.9	+4.4	+0.8	+1.5	+0.3	\$950
4	8678	S	QR	+2.7	+4.9	-0.3	+0.8	+0.8	\$800
5	8697	S	QR	+2.8	+4.8	0.0	+0.9	+1.0	\$850
Breed Average				+2.4	+4.1	+0.2	+0.6	+0.4	

1. Which	1. Which Ram is the most progressive across his genetic profile?								
1	2	3	4	5					
2. Of the	2. Of the clean blooded rams, who is the flattest and lightest muscled?								
1	2	3	4	5					
3. Which	3. Which Ram offers the least breeding value both on and off paper?								
1	2	3	4	5					
4. Which	h ram ha	as the mo	st bree	d charac	ter?				
1	2	3	4	5					
5. Which	h ram sh	ould bes	t compl	iment sp	peckle face ewes for the production of market lambs?				
1	2	3	4	5					
6. Of the	e Rams r	anging fo	or \$800-	\$950, w	hich ram is the least structurally correct?				
1	2	3 (4	5					
7. How	many Ra	ıms have	scrapie	?					
0	1	2	3	4	5				
		/pe for Fa		red's ew	re base is RR, how many of the rams will have sheep born				
0	1	2	3	4	5				
9. Who	9. Who is the slick legged, coarse, round-built ram off both ends of his skeleton?								
1	2	3	4	5					
10. Who	is the ta	llest fron	ted, lon	gest boo	died ram?				
1	2	3	4	5					



HERD BUILDER GOAT GROWER

The perfect ration for your show goats. This product will maximize your goats potential come show day.

For the prevention of coccidiosis caused by Eimeria crandallis, Eimeria christenseni and Eimeria ninakohlyakimovae in goats.

GUARANTEED ANALYSIS:

Crude Protein, min*16.5%
Crude Fat, min3.0%
Crude Fiber, max19.0%
Calcium, min0.7%
Calcium, max1.2%
Phosphorus, min0.3%
Salt, min0.6%
Salt, max1.1%
Vitamin A, min16,000 IU/lb
Vitamin D, min3,500 IU/lb
Vitamin E, min50 IU/lb
Selenium, min0.3 PPM
Acid Fiber Detergent, max25.0%
Copper, min15 PPM
Copper, max45 PPM

This includes not more than 1.2 % equivalent protein from non-protein nitrogen.*

Active Drug Ingredient:

Monensin.....20 G/TON

FEEDING INSTRUCTIONS:

Feed Herd Builder Goat Grower R20 as the sole ration. Feed to goats along with a good quality forage and clean, fresh drinking water.

CAUTION: Do not allow horses or other equines access to formulations containing Monensin. Ingestion of Monensin by equines has been fatal. Monensin-medicated cattle and goat feeds are safe for use in cattle and goats only. Consumption by unapproved species may result in toxic reactions. Do not exceed the levels of Monensin recommended in the feeding directions as reduced average daily gains may result.

WARNING: Do not feed to lactating goats.

INGREDIENTS:

Please refer to the product label/tag for a complete list of ingredients.

WARNING: This product, which contains added copper, should not be fed to sheep or related species that have a low tolerance to copper.

This product has been formulated specifically for goats and is not intended for other species.

Hubbard does not use "Restricted-use Proteins" in their products and is in compliance with FDA and state requirements regarding the use, handling and storage of "Restricted-use Protein" products.

PROFILE:

Herd Builder Goat Grower accelerates growth and development in doe kids, show does, donor does and breeding age bucks. Ideal ration for maintaining body condition and maximizing frame growth in breeding show does and bucks.

THIS IS A PRODUCT INFORMATION SHEET ONLY IN NO WAY SHOULD THIS BE UTILIZED AS A LABEL

Options in a 50lb bag #22433 or Bulk Invoice

Designed to enhance youthful bloom, accelerate growth and develop clean conformation in growing to older does, bucks and breeding through age mature does

GUARANTEED ANALYSIS:

Crude Protein, min*15.5%
Crude Fat, min4.0%
Crude Fiber, max19.0%
Calcium, min0.7%
Calcium, max1.2%
Phosphorus, min0.3%
Salt, min0.7%
Salt, max1.2%
Vitamin A, min16,000 IU/lb
Vitamin D, min3,500 IU/lb
Vitamin E, min50 IU/lb
Selenium, min0.3 PPM
Acid Fiber Detergent, max27.0%
Copper, min15 PPM
Copper, max65.0 PPM

This includes not more than 1.2 % equivalent protein from non-protein nitrogen.*

FEEDING INSTRUCTIONS:

Feed Duncan Fat "N" Sassy R20 as the sole ration. Feed to goats along with a good quality forage and clean, fresh drinking water.

CAUTION: Do not allow horses or other equines access to feed containing Monensin. Ingestion of Monensin by horses has been fatal. Monensin medicated cattle and goat feeds are safe for cattle and goats only. Consumption by unapproved species may result in toxic reactions. Do not exceed the levels of Monensin recommended in the feeding directions, as reduced average daily gains may result. Do not feed to lactating goats.

Hubbard does not use "Restricted-use Proteins" in their products and is in compliance with FDA and state requirements regarding the use, handling and storage of "Restricted-use Protein" products.

INGREDIENTS:

Please refer to the product label/tag for a complete list of ingredients.

WARNING: This product, which contains added copper, should not be fed to sheep or related species that have a low tolerance to copper. This product has been formulated specifically for goats and is not intended for other species.

Active Drug Ingredient:

Monensin.....20 G/TON

PROFILE:

An initial creep feed and starter for goats of all classes from birth to six months of age and for developing bucks and show does requiring extra bloom. Designed to enhance youthful bloom, accelerate growth and develop clean conformation in growing to older does, bucks and breeding through age mature does.

THIS IS A PRODUCT INFORMATION SHEET ONLY IN NO WAY SHOULD THIS BE UTILIZED AS A LABEL

Options in a 50lb bag #29148 or Bulk Invoice

ADVANCER PLUS R20

Show-Rite® Advancer Plus R20 promotes earlier bloom and smoother handle in sale wethers and jackpot goats. Advance maturity and muscularity in market goats at all stages of growth. Includes the daily recommended level of Rite-Factor already in the bag

For the prevention of coccidiosis caused by Eimeria crandallis, Eimeria christenseni and Eimeria ninakohlyakimovae in goats maintained in confinement.

GUARANTEED ANALYSIS:

Crude Protein, min*15.0%
Crude Fat, min3.5%
Crude Fiber, max12.0%
Calcium, min0.7%
Calcium, max1.2%
Phosphorus, min0.3%
Salt, min0.9%
Salt, max1.4%
Vitamin A, min8,000 IU/lb
Vitamin D, min900 IU/lb
Vitamin E, min190 IU/lb
Selenium, min0.3 PPM
Acid Fiber Detergent, max16.0%
Copper, min25 PPM
Copper, max75 PPM

This includes not more than 1.6 % equivalent protein from non-protein nitrogen.*

Active Drug Ingredient:

Monensin.....20 G/TON

FEEDING INSTRUCTIONS:

Feed Show-Rite Advancer® Plus R20 continuously as the sole ration to non-lactating goats. A source of good quality hay and a constant supply of clean fresh water is also required.

CAUTION: Do not allow horses or other equines access to formulations containing Monensin. Ingestion of Monensin by equines has been fatal. Do not feed undiluted. Monensin medicated cattle and goat feeds are safe for cattle and goats only. Consumption by unapproved species may result in toxic reactions. Must be thoroughly mixed in feed before use.

Do not exceed the levels of Monensin recommended in the feeding directions, as reduced average daily gains may result. Feeding undiluted or mixing errors resulting in high concentrations of Monensin has been fatal to cattle and could be fatal to goats.

WARNING: Do not feed to lactating goats.

INGREDIENTS:

Please refer to the product label/tag for a complete list of ingredients.

WARNING: This product, which contains added copper, should not be fed to sheep or related species that have a low tolerance to copper. This product has been formulated specifically for goats and is not intended for other species.

PROFILE:

Advancer PLUS has Rite-Factor Technology in the bag, and added barley for a smoother look and fresher handle desired in today's competitive show arena. Utilizing specific levels of protein and energy sources, this feed has a unique ability to "Advance" maturity, muscle development, and maximize genetic potential in show goats. Advancer PLUS contains Monensin (R20) to help combat Coccidiosis.

THIS IS A PRODUCT INFORMATION SHEET ONLY IN NO WAY SHOULD THIS BE UTILIZED AS A LABEL

Options in a 50lb bag #47855 or Bulk Invoice



G.O.A.T. R20

Texturized show goat feed, specially formulated for all life stages. Premium quality nutrition from Show-Rite, fortified with industry-leading Alltech Technologies designed to improve growth performance, reproduction, and overall animal health.

GUARANTEED ANALYSIS:

*Crude Protein, min	17.0%
Crude Fat, min	4.0%
Crude Fiber, max	12.0%
Acid Detergent Fiber, max	16.0%
Calcium, min	1.0%
Calcium, max	1.5%
Phosphorus, min	0.4%
Salt, min	0.5%
Salt, max	1.0%
Copper, min	13 ppm
Copper, max	43 ppm
Selenium, min	0.2 PPM
Vitamin A, min	6,600 IU/LB
Vitamin D, min	500 IU/LB
Vitamin E, min	160 IU/LB

^{*}This includes not more than 1.3 % equivalent protein from non-protein nitrogen

Active drug ingredients:

Monensin.....20 g/ton

FEEDING INSTRUCTIONS:

Feed Show-Rite G.O.A.T. R20 continuously to developing goats. Feed along with good quality forage. Provide a constant supply of clean, fresh water.

INGREDIENTS:

Please refer to the product label/tag for a complete list of ingredients.

WARNING: This product, which contains added copper, should not be fed to sheep or related species that have a low tolerance to copper.

This product has been formulated specifically for goats and is not intended for other species.

CAUTION: Do not allow horses or other equines access to formulations containing Monensin. Ingestion of Monensin by equines has been fatal. Do not feed undiluted. Monensin medicated cattle and goat feeds are safe for cattle and goats only. Consumption by unapproved species may result in toxic reactions. Must be thoroughly mixed in feed before use. Do not exceed the levels of Monensin recommended in the feeding directions, as reduced average daily gains may result. Feeding undiluted or mixing errors resulting in high concentrations of Monensin has been fatal to cattle and could be fatal to goats. Goat Type B Feeds: Goat Type C Feeds: Do not feed to lactating goats.

Hubbard does not use "Restricted-use Proteins" in their products and is in compliance with FDA and state requirements regarding the use, handling and storage of "Restricted-use Protein" products.

PROFILE:

- Texturized to enhance feed palatability
- Improves intake for pellet stubborn show goats
- Quick bloom for early prospect-bound goats
- Excellent transition feed for breeders
- Increase bloom in colder climates
- Explosive feed response, adding volume and cover to show does

THIS IS A PRODUCT INFORMATION SHEET ONLY IN NO WAY SHOULD THIS BE UTILIZED AS A LABEL Product # 65639 in a 50lb bag

Senior Team Feeding Judging Class – 2020

Names:	KEY	County
11a111631	rx= i	Oddity

(50 points possible)

ontestant Number4,3,2,1			_
acing Score			
iversity of Kentucky			
llege of Agriculture imal Sciences Department	А	1234	18
тш 5сіенсеѕ Берантені	В	1 2 4 3	20
	C	1324	23
ontestant's Name	D	1342	30
	E	1423	27
	F	1432	32
	G	2134	20
	Н	2 1 4 3	22
ldress	I	2 3 1 4	27
	J	2 3 4 1	36
	K	2413	31
	L	2 4 3 1	38
	M	3 1 2 4	30
ounty	N	3 1 4 2	37
	0	3 2 1 4	32
	P	3 2 4 1	41
	Q	3 4 1 2	46
ass	R	3 4 2 1	48
Feeding Class	S	4 1 2 3	36
	T	4 1 3 2	41
	U	4213	38
	V	4 2 3 1	45
	W	4 3 1 2	48
	X	4 3 2 1	50

Senior Team	Feeding Activity	<u>y Exercise – 2020</u>
	_	-

County:	KEY

Questions Score:

Team Members

Presentation Score:

Your team is advising a local 4-H exhibitor who just started showing goats this year. Your team initially helped the young exhibitor pick out his goat at the beginning of the year. Now that it is 60 days out until state fair the young man wants your team to look at the goat and give feeding advice. As your team evaluates the goat you notice several things. First the goat looks pretty full. It looks like the wether is practically bloated. Next your team handles the wether. Everyone agrees that the goat is plenty soft over his ribs. In reality he needs to be leaned up some. After that your team looks at his feed pan and water bucket. There is pelletized feed left in the pan and feces in the water bucket. Your team agrees that there are some serious changes that need to happen before the State Fair if this new 4-H exhibitor wants to be successful. Please rank the feeds (based off of the 4 feed product information sheets provided below) in the order that would best compliment the 4-H exhibitor's wether, going into the last 60 days before the state fair. Additionally, please answer the 5 questions below. Finally, your team will need to present to the official on your thoughts and any advice you would give the young 4-H exhibitor. (Ranking the feed correctly is worth 50 points. The 5 questions are worth 10 points each for a total of 50 points making the written portion worth a total of 100 points. The oral portion is worth 100 points for a Grand Total of 200 points.)

Assume all feeds are priced the same and all can be bought with the same availability.

Circle the answers to the questions below:

1.	Which feed is texturized?					
	Fat N Sassy R20	Advancer Plus R20	G.O.A.T. R20	Herd Builder Goat Grower	None	
2.	Which feed could be fed to	sheep?				
	Fat N Sassy R20	Advancer Plus R20	G.O.A.T. R20	Herd Builder Goat Grower	None	
3.	Monensin is provided in each	ch feed as a means to cor	mbat?			
<	Coccidiosis	Helminthiasis	Urinary Calculi	Soremouth		
4.	Which feed offers the most	protein?				
	Fat N Sassy R20	Advancer Plus R20	G.O.A.T. R20	Herd Builder Goat Grower		
5.	Which feed would maximize	e a mature buck you are ¡	preparing for show?			
	Fat N Sassy R20	Advancer Plus R20	G.O.A.T. R20	Herd Builder Goat Grower		

Indications: Cattle: For treatment and control of gastrointestinal roundworms. lungworms, eyeworms, grubs, sucking lice, and mange mites. Dectomax injectable solution has been proved to effectively control infections and to protect cattle from reinfection with Cooperia oncophora and Haemonchus placei for 14 days, Ostertagia ostertagi for 21 days, and C. punctata, Oesophagostomum radiatum, and Dictyocaulus viviparus for 28 days after treatment. Swine: For treatment and control of gastrointestinal roundworms, lungworms, kidney worms, sucking lice, and mange mites. See package insert for complete indications and directions for use.

Recommended Dose: Cattle: 1 mL (10 mg doramectin) per 110 lb of body weight (200 mcg/kg) administered by subcutaneous (SC) or intramuscular (IM) injection in the neck region. Beef Quality Assurance guidelines recommend SC administration as the preferred route. Swine: 1 mL (10 mg doramectin) per 75 lb of body weight (300 mcg/kg) administered by IM injection only.

Residue Warnings: Cattle: Do not slaughter for human consumption within 35 days of treatment. Not for use in female dairy cattle 20 months of age or older. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for yeal. Swine: Do not slaughter for human consumption within 24 days of treatment.

Precaution: For SC injection in cattle only. For IM injection in swine and cattle.

Store Below 30°C (86°F)

Disposal: Do not contaminate water by direct application or by improper disposal of drug containers. Dispose of containers in an approved landfill or by incineration.

Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

Not for human use

Restricted Drug (CA) Use only as directed.

Distributed by: Zoetis Inc. Kalamazoo, MI 49007

036254ZO

8186000 79-5197-00-9 Made in Brazil (doramectin)

Antiparasitic

1% injectable solution for cattle and swine

10 mg/mL

Net Contents: 200 mL

NADA #141-061, Approved by FDA



(tulathromycin injection) **Injectable Solution**

Antihiotic

25 mg of tulathromycin/mL

For use in suckling calves, dairy calves, veal calves, and swine. Not for use in ruminating cattle.

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

DRAXXIN 25 Injectable Solution is a ready-to-use sterile parenteral preparation containing tulathromycin, a semisynthetic macrolide antibiotic of the subclass triamilide. Each mL of DRAXXIN 25 contains 25 mg of tulathromycin as the free base in a 50% propylene glycol vehicle, monothioglycerol (5 mg/mL), citric acid (4.8 mg/mL) with hydrochloric acid and sodium hydroxide added to adjust pH. DRAXXIN 25 consists of an equilibrated mixture of two isomeric forms of tulathromycin in a 9:1 ratio.

The chemical names of the isomers are (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[[2,6-dideoxy-3-C-methyl-3-Omethyl-4-C-[(propylamino) methyl]- α -L-ribohexopyrano-syl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)]- β -D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one and (2R,3R,6R,8R,9R,10S,11S,12R)-11-[[2,6-dideoxy-3-C-methyl-3-O-methyl-4-C-[(propylamino)methyl]- α -L-ribohexopyrano-syl]oxy]-2-[(1R,2R)-1,2-dihydroxy-1-methylbutyl]-8-hydroxy-3,6,8,10,12-pentamethyl-9-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopyranosyl]oxy]-1-oxa-4-azacyclotridecan-13-one, respectively.

INDICATIONS

Swine

DRAXXIN 25 Injectable Solution is indicated for the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyppneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae. Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.

Suckling Calves, Dairy Calves, and Veal Calves

BRD - DRAXXIN 25 Injectable Solution is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.

DOSAGE AND ADMINISTRATION

Swine

Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (1 mL/22 lb) Body Weight (BW). Do not inject more than 4 mL per injection site.

Table 1. DRAXXIN 25 Swine Dosing Guide (25 mg/mL)

	3 (- 3- /
Animal Weight	Dose Volume
(Pounds)	(mL)
4	0.2
10	0.5
15	0.7
20	0.9
22	1.0
25	1.1
30	1.4
50	2.3
70	3.2
90	4.0

Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1 mL/22 lb) body weight (BW). Do not inject more than 11.5 mL per injection site.

Table 2. DRAXXIN 25 Calf Dosing Guide (25 mg/mL)

Animal Weight	Dose Volume
(Pounds)	(mL)
50	2.3
75	3.4
100	4.5
150	7.0
200	9.0
250	11.5

CONTRAINDICATIONS

The use of DRAXXIN 25 Injectable Solution is contraindicated in animals previously found to be hypersensitive to the drug

WARNINGS

FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN NOT FOR USE IN CHICKENS OR TURKEYS.

RESIDUE WARNINGS

Swine

Swine intended for human consumption must not be slaughtered within 5 days from the last treatment.

Calves intended for human consumption must not be slaughtered within 22 days from the last treatment with DRAXXIN 25 Injectable Solution. This drug is not for use in ruminating cattle.

PRECAUTIONS

Swine

The effects of Draxxin 25 Injectable Solution on porcine reproductive performance, pregnancy, and lactation have not been determined. Intramuscular injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.

The effects of Draxxin 25 Injectable Solution on bovine reproductive performance, pregnancy, and lactation have not been determined. Subcutaneous injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.

ADVERSE REACTIONS

In one field study, one out of 40 pigs treated with DRAXXIN Injectable Solution (100 mg/mL) at 2.5 mg/kg BW exhibited mild salivation that resolved in less than four hours.

Calves

In one BRD field study, two calves treated with DRAXXIN Injectable Solution (100 mg/mL) at 2.5 mg/kg BW exhibited transient hypersalivation. One of these calves also exhibited transient dyspnea, which may have been related to pneumonia

Post Approval Experience

The following adverse events are based on post approval adverse drug experience reporting for DRAXXIN Injectable Solution (100 mg/mL). Not all adverse events are reported to the FDA CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using these data. The following adverse events are listed in decreasing order of reporting frequency in cattle: Injection site reactions and anaphylaxis/anaphylactoid reactions. For a complete listing of adverse reactions for DRAXXIN Injectable Solution or DRAXXIN 25 Injectable Solution reported to the CVM see: http://www.fda.gov/AnimalVeterinary.

CLINICAL PHARMACOLOGY

At physiological pH, tulathromycin (a weak base) is approximately 50 times more soluble in hydrophilic than lipophilic media. This solubility profile is consistent with the extracellular pathogen activity typically associated with the macrolides. Markedly higher tulathromycin concentrations are observed in the lung parenchyma as compared to the plasma, and these elevated concentrations can remain in lung tissue for several days beyond that which can be measured in the plasma. However the clinical relevance of these elevated lung concentrations is undetermined.

As a class, macrolides tend to be primarily bacteriostatic, but may be bactericidal against some pathogens.2 When acting as a cidal compound, they tend to exhibit concentration independent killing; the rate of bacterial eradication does not change once serum drug concentrations reach 2 to 3 times the minimum inhibitory concentration (MIC) of the targeted pathogen. Under these conditions, the time that serum concentrations remain above the MIC becomes the major determinant of antimicrobial activity. Macrolides also exhibit a post-antibiotic effect (PAE), the duration of which tends to be both drug and pathogen dependent. In general, by increasing the macrolide concentration and the exposure time, the PAE will increase to some maximal duration.³ Tulathromycin is eliminated from the body primarily unchanged via biliary excretion.

- Carbon, C. 1998. Pharmacodynamics of Macrolides, Azalides, and Streptogramins: Effect on Extracellular Pathogens. Clin. Infect. Dis., 27:28-32.
- ² Nightingale, C.J. 1997. Pharmacokinetics and Pharmacodynamics of Newer Macrolides. Pediatr. Infect. Dis. J., **16**:438-443
- ³ Andes D, Anon J, Jacobs MR, Craig WA. (2004). Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clin Lab Med., 24:477-502.

Following intramuscular (IM) administration to feeder pigs at a dosage of 2.5 mg/kg BW, tulathromycin is nearly completely absorbed, with peak plasma concentrations achieved within ~0.25 hr. The volume of distribution exceeds 15 L/kg, which is consistent with extensive tissue binding. This large distribution volume results in a long terminal elimination half- life (60 to 90 hours) despite a rapid systemic free drug clearance (187 mL/kg/hr). There are no gender differences in swine tulathromycin pharmacokinetics.

Comparative Bioavailability Summary

Despite slightly lower peak concentrations with DRAXXIN 25 Injectable Solution, a single IM dose of 2.5 mg tulathromycin/kg BW of either DRAXXIN Injectable Solution (100 mg/mL) or DRAXXIN 25 Injectable Solution (25 mg/mL) resulted in comparable tulathromycin total systemic exposure. Therefore, DRAXXIN 25 Injectable Solution is considered to be therapeutically equivalent to DRAXXIN Injectable Solution when administered to swine by IM injection at a dose of 2.5 mg tulathromycin/kg BW.

Calves

Following subcutaneous (SC) administration into the neck of feeder calves at a dosage of 2.5 mg/kg BW, tulathromycin is nearly completely absorbed, with peak plasma concentrations achieved within ~0.25 hr. The volume of distribution exceeds 11 L/kg4, which is consistent with extensive tissue binding. This large distribution volume results in a long terminal elimination half-life of more than 100 hours, despite a rapid systemic free drug clearance (170 mL/kg/hr). No pharmacokinetic differences are observed in castrated male versus female calves.

Comparative Bioavailability Summary

Despite lower peak concentrations with DRAXXIN 25 Injectable Solution, a single SC dose of 2.5 mg tulathromycin/kg BW of either DRAXXIN Injectable Solution (100 mg/mL) or DRAXXIN 25 Injectable Solution (25 mg/mL) resulted in comparable total systemic tulathromycin exposure. Therefore, DRAXXIN 25 Injectable Solution is considered to be therapeutically equivalent to DRAXXIN Injectable Solution when administered to calves by SC injection at a dose of 2.5 mg tulathromycin/kg BW.

⁴ Clearance and volume estimates are based on intersubject comparisons of 2.5 mg/kg BW administered by either subcutaneous or intravenous injection.

MICROBIOLOGY

Swine

Tulathromycin has demonstrated *in vitro* activity against *A. pleuropneumoniae, P. multocida, B. bronchiseptica*, H. parasuis, and M. hyopneumoniae. The MICs of tulathromycin against indicated pathogens collected from field studies were determined using methods recommended by the Clinical and Laboratory Standards Institute (CLSI, M31-A and M31-A3). MICs for H. parasuis were determined using Veterinary Fastidious Medium and were incubated up to 48 hours at 35 to 37°C in a CO2-enriched atmosphere. These values are represented in Table 3, below.

Table 3. Tulathromycin minimum inhibitory concentration (MIC) values* for indicated pathogens isolated from field studies evaluating SRD in the U.S. and Canada.

Indicated pathogen	Date isolated	No. of isolates	MIC ₅₀ ** (μg/mL)	MIC ₉₀ ** (µg/mL)	MIC range (μg/mL)
Actinobacillus pleuropneumoniae	2000-2002 2007-2008	135 88	16 16	32 16	16 to 32 4 to 32
Haemophilus parasuis	2000-2002	31	1	2	0.25 to > 64
Pasteurella	2000-2002	55	1	2	0.5 to> 64
multocida Bordetella bronchiseptica	2007-2008 2000-2002	40 42	4	8	≤ 0.03 to 2 2 to 8

Tulathromycin has demonstrated *in vitro* activity against *M. haemolytica, P. multocida, H. somni,* and *M. bovis*, four pathogens associated with BRD. The MICs of tulathromycin against indicated pathogens collected from field studies using DRAXXIN Injectable Solution (100 mg/mL) were determined using methods recommended by the CLSI (M31-A2). These values are represented in Table 4, below.

^{*}The correlation between *in vitro* susceptibility data and clinical effectiveness is unknown.

** The lowest MIC to encompass 50% and 90% of the most susceptible isolates, respectively.

Table 4. Tulathromycin minimum inhibitory concentration (MIC) values* for indicated pathogens isolated from field studies evaluating BRD in the U.S.

Indicated pathogen	Date isolated	No. of isolates	MIC ₅₀ ** (μg/mL)	MIC ₉₀ ** (µg/mL)	MIC range (µg/mL)
Mannheimia haemolytica	1999	642	2	2	0.5 to 64
Pasteurella multocida	1999	221	0.5	1	0.25 to 64
Histophilus somni	1999	36	4	4	1 to 4
Mycoplasma bovis	1999	43	0.125	1	≤ 0.063 to > 64

- * The correlation between in vitro susceptibility data and clinical effectiveness is unknown.
- ** The lowest MIC to encompass 50% and 90% of the most susceptible isolates, respectively.

EFFECTIVENESS

Swine

Plasma concentrations of tulathromycin administered as DRAXXIN Injectable Solution (100 mg/mL) or as DRAXXIN 25 Injectable Solution were demonstrated to be therapeutically equivalent (see CLINICAL PHARMACOLOGY, Comparative Bioavailability Summary). Therefore effectiveness studies conducted with DRAXXIN Injectable Solution (100 mg/mL) support the effectiveness for DRAXXIN 25 Injectable Solution.

In a multi-location field study to evaluate the treatment of naturally occurring SRD, 266 pigs were treated with DRAXXIN Injectable Solution (100 mg/mL). Responses to treatment were compared to saline-treated controls. Success was defined as a pig with normal attitude, normal respiration, and rectal temperature of < $104^{\circ}F$ on Day 7. The treatment success rate was significantly greater ($P \le 0.05$) in DRAXXIN-treated pigs (70.5°) compared to saline-treated pigs (46.1°). *M. hyopneumoniae* was isolated from 106 saline-treated and non-treated sentinel pigs in this study.

Two induced infection model studies were conducted to confirm the effectiveness of DRAXXIN Injectable Solution (100 mg/mL) against *M. hyopneumoniae*. Ten days after inoculation intranasally and intratracheally with a field strain of *M. hyopneumoniae*, 144 pigs were treated with either DRAXXIN (2.5 mg/kg BW) intramuscularly or an equivalent volume of saline. Pigs were euthanized and necropsied 10 days post-treatment. The mean percentage of gross pneumonic lung lesions was statistically significantly lower (P < 0.0001) for DRAXXIN-treated pigs than for saline-treated pigs in both studies (8.52% vs. 23.62% and 11.31% vs. 26.42%).

The effectiveness of DRAXXIN Injectable Solution (100 mg/mL) for the control of SRD was evaluated in a multi-location natural infection field study. When at least 15% of the study candidates showed clinical signs of SRD, all pigs were enrolled and treated with DRAXXIN (226 pigs) or saline (227 pigs). Responses to treatment were evaluated on Day 7. Success was defined as a pig with normal attitude, normal respiration, and rectal temperature of < 104° F. The treatment success rate was significantly greater (P < 0.05) in DRAXXIN-treated pigs compared to saline-treated pigs (59.2% vs. 41.2%).

Calves

Plasma concentrations of tulathromycin administered as DRAXXIN Injectable Solution (100 mg/mL) or as DRAXXIN 25 Injectable Solution were demonstrated to be therapeutically equivalent (see CLINICAL PHARMACOLOGY, Comparative Bioavailability Summary). Therefore effectiveness studies conducted with DRAXXIN Injectable Solution (100 mg/mL) support the effectiveness for DRAXXIN 25 Injectable Solution.

BRD - In a multi-location field study, 314 calves with naturally occurring BRD were treated with DRAXXIN Injectable Solution (100 mg/mL). Responses to treatment were compared to saline-treated controls. A cure was defined as a calf with normal attitude/activity, normal respiration, and a rectal temperature of $s=104^{\circ}$ F on Day 14. The cure rate was significantly higher (P s=0.05) in DRAXXIN-treated calves (78%) compared to saline-treated calves (24%). There were two BRD-related deaths in the DRAXXIN-treated calves compared to nine BRD-related deaths in the saline-treated calves.

Fifty-two DRAXXIN Injectable Solution (100 mg/mL)-treated calves and 27 saline-treated calves from the multilocation field BRD treatment study had *Mycoplasma bovis* identified in cultures from pre-treatment nasopharyngeal swabs. Of the 52 DRAXXIN-treated calves, 37 (71.2%) calves were categorized as cures and 15 (28.8%) calves were categorized as treatment failures. Of the 27 saline-treated calves, 4 (14.8%) calves were categorized as cures and 23 (85.2%) calves were treatment failures.

A Bayesian meta-analysis was conducted to compare the BRD treatment success rate in young calves (calves weighing 250 lbs or less and fed primarily a milk-based diet) treated with DRAXXIN Injectable Solution (100 mg/mL) to the success rate in older calves (calves weighing more than 250 lbs and fed primarily a roughage and grain-based diet) treated with DRAXXIN. The analysis included data from four BRD treatment effectiveness studies conducted for the approval of DRAXXIN Injectable Solution (100 mg/mL) in the U.S. and nine contemporaneous studies conducted in Europe. The analysis showed that the BRD treatment success rate in young calves was at least as good as the BRD treatment success rate in older calves. As a result, DRAXXIN Injectable Solution (100 mg/mL) was considered effective for the treatment of BRD associated with *M. haemolytica, P. multocida, H. sommi, and M. bovis* in suckling calves, dairy calves, and veal calves.

Two induced infection model studies were conducted to confirm the effectiveness of DRAXXIN Injectable Solution (100 mg/mL) against *Mycoplasma bovis*. A total of 166 calves were inoculated intratracheally with field strains of *Mycoplasma bovis*. When calves became pyrexic and had abnormal respiration scores, they were treated with either DRAXXIN (2.5 mg/kg BW) subcutaneously or an equivalent volume of saline. Calves were observed for signs of BRD for 14 days post-treatment, then were euthanized and necropsied. In both studies, mean lung lesion percentages were statistically significantly lower in the DRAXXIN-treated calves compared with saline-treated calves (11.3% vs. 28.9%, P = 0.0001 and 15.0% vs. 30.7%, P < 0.0001).

ANIMAL SAFETY

Swine

Plasma concentrations of tulathromycin administered as DRAXXIN Injectable Solution (100 mg/mL) or as DRAXXIN 25 Injectable Solution were demonstrated to be therapeutically equivalent (see CLINICAL PHARMACOLOGY, Comparative Bioavailability Summary). Therefore systemic target animal safety studies conducted with DRAXXIN Injectable Solution support the systemic safety for DRAXXIN 25 Injectable Solution.

Safety studies were conducted in pigs receiving a single intramuscular dose of 25 mg/kg BW, or 3 weekly intramuscular doses of 2.5, 7.5, or 12.5 mg/kg BW (both studies utilized DRAXXIN Injectable Solution (100 mg/mL)). In all groups, transient indications of pain after injection were seen, including restlessness and excessive vocalization. Tremors occurred briefly in one animal receiving 7.5 mg/ kg BW. Discoloration and edema of injection site tissues and corresponding histopathologic changes were seen in animals at all dosages and resolved over time. No other drug-related lesions were observed macroscopically or microscopically.

Sixteen growing pigs were injected with either saline or DRAXXIN 25 Injectable Solution as a single injection of 4 mL. Injection site observations included two instances of erythema in the DRAXXIN 25-treated group on Day 1 post-injection. No heat, sensitivity, firmness, necrosis, drainage, or swelling was observed at any injection sites in either treatment group. The gross and microscopic findings in the DRAXXIN 25-treated group were consistent with inflammatory changes induced by injections and were considered to be mild or moderate with progression to macroscopic resolution by Day 28 post-injection and microscopic resolution by Day 42 post-injection.

Calves

Plasma concentrations of tulathromycin administered as DRAXXIN Injectable Solution (100 mg/mL) or as DRAXXIN 25 Injectable Solution were demonstrated to be therapeutically equivalent (see CLINICAL PHARMACOLOGY, Comparative Bioavailability Summary). Therefore effectiveness studies conducted with DRAXXIN Injectable Solution support the effectiveness for DRAXXIN 25 Injectable Solution.

A safety study was conducted in feeder calves receiving DRAXXIN Injectable Solution (100 mg/mL) as a single subcutaneous dose of 25 mg/kg BW, or 3 weekly subcutaneous doses of 2.5, 7.5, or 12.5 mg/kg BW. In all groups, transient indications of pain after injection were seen, including head shaking and pawing at the ground. Injection site swelling, discoloration of the subcutaneous tissues at the injection site and corresponding histopathologic changes were seen in animals in all dosage groups. These lesions showed signs of resolving over time. No other drug-related lesions were observed macroscopically or microscopically.

An exploratory study was conducted in feeder calves receiving DRAXXIN Injectable Solution (100 mg/mL) as a single subcutaneous dose of 10, 12.5, or 15 mg/kg BW. Macroscopically, no lesions were observed. Microscopically, minimal to mild myocardial degeneration was seen in one of six calves administered 12.5 mg/kg BW and two of six calves administered 15 mg/kg BW.

A safety study was conducted in preruminant calves 13 to 27 days of age receiving DRAXXIN Injectable Solution (100 mg/mL) at 2.5 mg/kg BW or 7.5 mg/kg BW once subcutaneously. With the exception of minimal to mild injection site reactions, no drug-related clinical signs or other lesions were observed macroscopically or microscopically.

Sixteen growing cattle were injected with either saline (eight animals) as a single injection of 11.5 mL or DRAXXIN 25 Injectable Solution (eight animals) as a single injection of either 2.5 mg/kg BW or a dose volume of 11.5 mL (whichever volume was higher). One calf in the DRAXXIN 25-treated group was observed to have firmness at the injection site for a single day. Two DRAXXIN 25-treated calves exhibited injection site swelling. In one calf, the swelling resolved within 48 hours. In the other calf, the swelling was observed over a three-day period, after which the calf underwent a scheduled necropsy, preventing further injection site observations. No injection site swelling was observed in saline-treated animals. At necropsy, three of the saline-treated calves and five of the DRAXXIN 25-treated calves had altered tissue present at the injection site. The gross and microscopic findings in the DRAXXIN 25-treated group were consistent with inflammatory changes induced by injections, were considered to be mild to marked, and progressed to macroscopic resolution and microscopic resolution by Day 42 post-injection.

STORAGE CONDITIONS:

Store at or below 25°C (77°F). Use within 90 days of first vial puncture.

HOW SUPPLIED

DRAXXIN 25 Injectable Solution is available in the following package sizes: 50 mL vial 100 mL vial 250 mL vial

NADA 141-349, Approved by FDA



Distributed by: Zoetis Inc. Kalamazoo, MI 49007

To report a suspected adverse reaction or to request a safety data sheet call 1-888-963-8471. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/AnimalVeterinary/SafetyHealth.

For additional DRAXXIN 25 product information call: **1-888-DRAXXIN** or go to www.DRAXXIN.com



Made in Brazil Revised: September 2014

060005AAA&P

MERCK ANIMAL HEALTH

Intervet Inc.

2 GIRALDA FARMS, MADISON, NJ, 07940

 Customer Service:
 800-521-5767

 Order Desk:
 800-648-2118

 Technical Service (Companion Animal):
 800-224-5318

 Technical Service (Livestock):
 800-211-3573

 Fax:
 973-937-5557

Website: www.merck-animal-health-usa.com



Every effort has been made to ensure the accuracy of the information published. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the USA product label or package insert.

Banamine®-S



Intervet/Merck Animal Health

PRODUCT INFORMATION

NADA #101-479, Approved by FDA.

(flunixin meglumine injection)

50 mg/mL

Veterinary

For intramuscular use in swine.

Not for use in breeding swine.

CAUTION

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION

Each milliliter of BANAMINE-S (flunixin meglumine injection) contains 50 mg flunixin (equivalent to 83 mg flunixin meglumine), 0.1 mg edetate disodium, 2.5 mg sodium

formaldehyde sulfoxylate, 4.0 mg diethanolamine, 207.2 mg propylene glycol; 5.0 mg phenol as preservative, hydrochloric acid, water for injection q.s.

CLINICAL PHARMACOLOGY

Flunixin meglumine is a potent non-narcotic, nonsteroidal, analgesic agent with antiinflammatory and antipyretic activity. It is significantly more potent than pentazocine, meperidine, and codeine as an analgesic in the rat yeast paw test.

Flunixin is known to persist in inflammatory tissues¹ and is associated with anti-inflammatory properties which extend well beyond the period associated with detectable plasma drug concentrations². Therefore, prediction of drug concentrations based upon estimated plasma terminal elimination half-life will likely underestimate both the duration of drug action and the concentration of drug remaining at the site of activity.

The pharmacokinetic profiles were found to follow a 2-compartmental model, although a deep (third) compartment was observed in some animals. The mean terminal elimination half-life (β half-life) of flunixin after a single intramuscular injection of Banamine (2.2 mg/kg) to pigs was between 3 and 4 hours. The mean observed maximum plasma concentration was 2944 ng/mL, achieved at a mean time of approximately 0.4 hours. The mean AUC_(0-LOQ) was 6431 ng*hr/mL. Following IM administration of flunixin, quantifiable drug concentration could be measured up to 18 hours post dose. The mean volume of distribution was 2003 mL/kg and the mean total clearance was 390 mL/hr/kg. The mean absolute bioavailability of flunixin following an intramuscular injection in the neck was 87%.

INDICATION

BANAMINE-S (flunixin meglumine injection) is indicated for the control of pyrexia associated with swine respiratory disease.

DOSE AND ADMINISTRATION

The recommended dose for swine is 2.2 mg/kg (1 mg/lb; 2 mL per 100 lbs) body weight given by a single intramuscular administration. The injection should be given only in the neck musculature with a maximum of 10 mL per site.

USE WITHIN 28 DAYS OF FIRST PUNCTURE AND PUNCTURE A MAXIMUM OF 10 TIMES. WHEN USING A DRAW-OFF SPIKE OR NEEDLE WITH BORE DIAMETER LARGER THAN 18 GAUGE, DISCARD ANY PRODUCT REMAINING IN THE VIAL IMMEDIATELY AFTER USE.

Note: Intramuscular injection may cause local tissue irritation and damage. In an injection-site irritation study, the tissue damage did not resolve in all animals by Day 28 post-injection. This may result in trim loss of edible tissue at slaughter.

CONTRAINDICATIONS

There are no known contraindications to this drug in swine when used as directed. Do not use in animals showing hypersensitivity to flunixin meglumine. Use judiciously when renal impairment or gastric ulceration is suspected.

RESIDUE WARNINGS

Swine must not be slaughtered for human consumption within 12 days of the last treatment.

PRECAUTIONS

As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Patients at greatest risk for adverse events are those that are dehydrated, on concomitant diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached. NSAIDs may inhibit the prostaglandins that maintain normal homeostatic function. Such prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease that has not been previously diagnosed.

Since many NSAIDs possess the potential to produce gastrointestinal ulceration, concomitant use of flunixin meglumine with other anti-inflammatory drugs, such as other NSAIDs and corticosteroids, should be avoided.

Not for use in breeding swine. The reproductive effects of BANAMINE-S (flunixin meglumine injection) have not been investigated in this class of swine.

Intramuscular injection may cause local tissue irritation and damage. In an injection site irritation study, the tissue damage did not resolve in all animals by Day 28 post-injection. This may result in trim loss of edible tissue at slaughter.

ADVERSE REACTIONS

Flunixin was mildly irritating at the injection sites. No other flunixin-related changes (adverse reactions) were noted in swine administered a 1X (2.2 mg/kg; 1.0 mg/lb) dose for 9 days.

ANIMAL SAFETY

Minimal toxicity manifested itself as statistically significant increased spleen weight at elevated doses (5X or higher daily for 9 days) with no change in normal microscopic architecture.

HOW SUPPLIED

BANAMINE-S (flunixin meglumine injection), 50 mg/mL is available in 100-mL (NDC # 0061-1838-30) multi-dose vials.

Store at or below 25° C (77°F). Do not freeze.

See the In-Use statement as provided in the Dose and Administration section.

- 1. Lees P, Higgins AJ. Flunixin inhibits prostaglandin E₂ production in equine inflammation. *Res Vet Sci.* 1984; 37:347-349.
- 2. Odensvik K. Pharmacokinetics of flunixin and its effect on prostaglandin $F_{2\alpha}$ metabolite concentrations after oral and intravenous administration in heifers. *J Vet Pharmacol Ther*. 1995; 18:254-259.

Distributed by: Intervet Inc d/b/a Merck Animal Health, Madison, NJ 07940

Copyright © 2011 Intervet Inc., a subsidiary of

Merck & Co., Inc.

All rights reserved.

Made in Germany

Rev. 01/17

180996 R3

CPN: 1047251.2

County	KEY
Team Members	

Senior Team Quality Assurance Exercise – 2020

You are a farm to fork hog operation. Your operation has really taken off with the push for locally sourced pork products. Just like any operation you have your share of animals that get sick. Currently you have 3 hogs that are in your treated pen. These three hogs have been spoken for by local buyers and they would like to have their product as soon as possible. You mentioned you would go through your routine quality assurance check list and let them know if the hogs could go to slaughter on 2/24/2020. Using the three (3) medication inserts provided, answer the questions below and finish filling in the table of treatment records on the reverse side of this page. Once the table is filled in, please draw the ear notches on the three pig heads below to confirm you know who each pig is. A calendar is provided for your use as well. (Each answer is worth 7 points each for a total of 140 points, plus each ear correctly notched is worth 10 points each for a total of 60 points. Total points for exercise=200)

NOTES ON TREATMENTS:


- Assume you accurately followed the directions on the medication insert.
- Assume the treatment date given in the treatment records is the last date of treatment
- If a range of recommended dosage is given on the medication insert, assume you gave the highest dosage recommended
- 1) Which medication is a parasiticide? **Dectomax**
- 2) When giving Banamine-S, what's the largest amount that should be administered in 1 site? 10 mL
- 3) Which of the medications should not be given to sheep? None of the medications should be given
- 4) Which of the medications has an adverse reaction of hogs with mild salivation that resolved in less than four hours? **Draxxin 25**
- 5) Which of the medications is made in Germany? **Banamine-S**

TREATMENT RECORD

Treatment Date	Hog Treated (Ear Notch)	Hog Weight	Medication Given	Route Given	Amount Given	Required Withdrawal Period (days)	Date Withdrawal Complete	Can Hog Be Sold on 2/24/20 (yes or no)
1/27/20	74-5	250 lbs	Banamine - S	IM	5 ml	12 days	02/08/20	yes
2/15/20	15-8	290 lbs	Draxxin 25	IM	13.18 or 13.2 ml	5 days	02/20/20	yes
1/15/20	106-10	220 lbs	Dectomax	IM	2.93 or 2.9 ml	24 Days	02/08/20	yes

Intramuscular = IM Subcutaneous = SC Intravenous = IV Topical = T Added to feed = F

Please notch the hogs below. There notches will be listed above each head. Please use the following symbol in the area of the ear you want notched: > Each ear worth 10 points a piece.



CALENDAR

Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
December 1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31	January 1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31	February 1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29